Clinical Trial Update: Efficacy and Safety of MW031 in PMO Subjects [Phase 3]

View source ↗

Summary

Phase 3 trial update on MW031 for osteoporosis in postmenopausal patients completed, reporting efficacy and safety results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Osteoporosis
• Postmenopausal Osteoporosis

Drugs mentioned

• MW031

Snippet

Sponsor: Mabwell (Shanghai) Bioscience Co., Ltd. | Conditions: Osteoporosis, Postmenopausal | Phase 3 | Status: COMPLETED